Search

Sarepta Therapeutics Inc

Lezárt

SzektorEgészségügy

18.8 4.27

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

17.86

Maximum

18.69

Fő mutatók

By Trading Economics

Bevétel

-4.9M

326M

Értékesítés

-330M

401M

P/E

Szektor átlag

42.919

57.371

Egy részvényre jutó nyereség

0.42

Profit margin

81.263

Munkavállalók

835

EBITDA

-345M

30M

Ajánlások

By TipRanks

Ajánlások

Semleges

12 hónapos előrejelzés

+21.71% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 2.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

244M

1.9B

Előző nyitás

14.53

Előző zárás

18.8

Hangulat hírek alapján

By Acuity

50%

50%

147 / 340 Rangsor szerint Healthcare

Sarepta Therapeutics Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 21. 19:26 UTC

Sarepta Therapeutics Inc is trading lower today, with no specific news identified for the decline. Broader market trends show a rebound in U.S. stocks.

2026. aug. 20. 23:56 UTC

Sarepta Therapeutics Inc. shares traded roughly flat in after-market hours, remaining above their 20-day moving average and near the upper end of their one-month range.

2026. aug. 19. 23:11 UTC

Sarepta Therapeutics shares are lower in after-market hours amid a broader decline in the Biotechnology sub-sector, showing unusual volatility during the session.

2026. aug. 18. 23:11 UTC

Sarepta Therapeutics Inc shares are lower in after-market hours, retracing gains amid broader market weakness linked to rising sovereign bond yields and inflation concerns.

2026. aug. 17. 19:36 UTC

Sarepta Therapeutics Inc shares are higher, continuing their advance since Friday's close and trading above the 20-day moving average. No specific news was identified.

2026. aug. 14. 19:36 UTC

Sarepta Therapeutics shares are lower today amid broader market sentiment following a reported decline in retail sales for July. No specific company news was identified.

2026. aug. 13. 19:36 UTC

Sarepta Therapeutics shares are trading roughly flat, with no specific news identified. The price remains significantly above the 20-day moving average.

2026. aug. 12. 23:51 UTC

Sarepta Therapeutics Inc shares are lower in after-market hours, continuing a decline since Wednesday's close, with no specific news identified to explain the drop.

2026. aug. 11. 23:51 UTC

Sarepta Therapeutics Inc shares are lower in after-market trading. No specific news was identified to explain the movement amid broader market focus on inflation data.

2026. aug. 10. 23:52 UTC

Sarepta Therapeutics shares are lower in after-market hours, with no specific news identified for the decline amid broader market sentiment influenced by labor report data.

2026. aug. 7. 19:36 UTC

News

Sarepta Therapeutics reports Q2 2026 revenue of $401.3 million, down from $611.1 million a year earlier, with shares trading lower during the session.

2026. aug. 6. 20:03 UTC

Social Media
News

Sarepta Therapeutics shares are higher following strong Q2 results, with adjusted EPS of $0.64 and revenue of $401.3 million exceeding estimates.

2026. aug. 5. 23:11 UTC

News
Social Media

Sarepta Therapeutics reported Q2 adjusted EPS of $0.64, exceeding estimates. Revenue reached $401.3 million, driving shares higher in after-market trading.

2026. aug. 4. 19:31 UTC

Sarepta Therapeutics is higher today, benefiting from strong tech stock performance and increased U.S. manufacturing activity, despite pulling back earlier in the session.

2026. aug. 3. 20:03 UTC

Sarepta Therapeutics Inc shares are higher today, reflecting broader market strength. The S&P 500 and Nasdaq 100 have also advanced during the session.

2026. júl. 30. 19:58 UTC

Sarepta Therapeutics Inc shares are lower today, with no specific news driving the decline. The stock is trading significantly below its 20-day moving average.

2026. júl. 29. 22:06 UTC

News

Sarepta Therapeutics granted inducement stock options to CEO Dr. Michael Severino, with shares trading higher in after-market hours following the announcement.

2026. júl. 28. 23:11 UTC

Sarepta Therapeutics Inc shares are lower in after-market hours amid a broader market decline, with no specific news identified to explain the movement.

2026. júl. 27. 23:16 UTC

Social Media

Sarepta Therapeutics appoints Michael Severino as CEO, effective July 28. Shares are higher in after-market trading following the leadership change.

2026. júl. 21. 17:51 UTC

Sarepta Therapeutics shares are lower today, pulling back from earlier session highs amid no specific news. The stock remains near the lower end of its one-month range.

Társak összehasonlítása

Árváltozás

Sarepta Therapeutics Inc Előrejelzés

Célár

By TipRanks

21.71% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 22.87 USD  21.71%

Magas 38 USD

Alacsony 5 USD

16 Wall Street elemző 12 hónapos célárain alapulva a(z)Sarepta Therapeutics Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Semleges

16 ratings

5

Vétel

7

Tartás

4

Eladás

Hangulat

By Acuity

147 / 340 Rangsor szerint Egészségügy

Hangulat hírek alapján

Neutral

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat